UCLA researchers have identified a BMP binding peptide that binds to bone growth factors to increase their residence time at the site of implantation for treatment of bone defects.
Bone morphogenetic proteins (BMPs) are a group of growth factors that are able to induce the formation of bone and cartilage. Delivery of recombinant BMPs using a carrier substance heals bone defects in many animals, and FDA approval was granted for the clinical use of recombinant human bone morphogenetic protein-2 (rhBMP-2) to enhance anterior cervical spinal fusion. Although BMPs are potent osteoinductive agents, large amounts of BMPs are required to produce an adequate biologic response in humans. Thus, BMPs in clinical use are quite expensive. Furthermore, large amounts of BMPs may cause local adverse effects, such as soft tissue inflammatory reactions. These factors limit the clinical utility of BMPs.
UCLA researchers have identified a cyclic peptide termed BMP binding peptide (BBP). BBP binds to bone growth factors, specifically BMP-2, and enhances the activity of the growth factor by increasing its residence time at the site of implantation.
BBP has been developed and tested. Studies are underway to identify modifications that will allow BBP to strongly complex with collagen or other carrier inert material. The complexed carriers are in the conceptual phase.
BMP, BBP, bone growth factors, implantation, carrier, residence time